Compare MSI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSI | ARGX |
|---|---|---|
| Founded | 1928 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3B | 51.1B |
| IPO Year | N/A | 2017 |
| Metric | MSI | ARGX |
|---|---|---|
| Price | $372.29 | $893.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | $502.50 | ★ $925.94 |
| AVG Volume (30 Days) | ★ 1.6M | 348.9K |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 36.31 | N/A |
| EPS | 12.46 | ★ 23.27 |
| Revenue | ★ $11,313,000,000.00 | $3,683,281,000.00 |
| Revenue This Year | $8.75 | $91.22 |
| Revenue Next Year | $8.25 | $36.36 |
| P/E Ratio | ★ $29.75 | $35.81 |
| Revenue Growth | 6.18 | ★ 92.98 |
| 52 Week Low | $365.40 | $510.06 |
| 52 Week High | $492.22 | $934.62 |
| Indicator | MSI | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 31.01 | 51.14 |
| Support Level | $369.05 | $886.50 |
| Resistance Level | $374.94 | $917.71 |
| Average True Range (ATR) | 6.24 | 17.58 |
| MACD | 2.51 | -6.77 |
| Stochastic Oscillator | 37.89 | 7.87 |
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.